- Home
- RGNX vs GBLI Comparison
RGNX vs GBLI Comparison
Compare RGNX & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RGNX | GBLI |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.1M | 395.4M |
| IPO Year | 2015 | 2010 |
Fundamental Metrics
Financial Performance| Metric | RGNX | GBLI |
|---|---|---|
| Price | $8.76 | $27.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $28.75 | N/A |
| AVG Volume (30 Days) | ★ 501.7K | 1.3K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 5.04% |
| EPS Growth | ★ 18.08 | N/A |
| EPS | N/A | ★ 1.75 |
| Revenue | $10,393,000.00 | ★ $450,098,000.00 |
| Revenue This Year | $51.21 | $14.23 |
| Revenue Next Year | $19.08 | $9.68 |
| P/E Ratio | ★ N/A | $15.89 |
| Revenue Growth | ★ 126.48 | 2.02 |
| 52 Week Low | $6.89 | $25.88 |
| 52 Week High | $16.19 | $34.00 |
Technical Indicators
Market Signals| Indicator | RGNX | GBLI |
|---|---|---|
| Relative Strength Index (RSI) | 46.91 | 45.62 |
| Support Level | $8.68 | $27.49 |
| Resistance Level | $9.29 | $29.76 |
| Average True Range (ATR) | 0.48 | 0.45 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 28.57 | 49.66 |
Price Performance
Historical ComparisonAbout RGNX REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC is a United States-based holding company with a diversified portfolio of property and casualty insurance-related entities. Along with its subsidiaries, the company operates in the following reportable segments: Agency and Insurance Services, Belmont Insurance Companies - Core (Belmont Core), and Belmont Insurance Companies - Non-Core (Belmont Non-Core). Maximum revenue is generated from the Belmont Core segment, which offers direct insurance and assumed reinsurance products in the E&S (Excess and Surplus) marketplace. The Agency and Insurance Services segment is focused on sourcing, underwriting, and servicing primary and assumed reinsurance business; and specialized insurance service businesses providing technology, AI-enabled marketplace, and claims services.